Stents succeed in heart attack pilot studies
This article was originally published in Clinica
Executive Summary
Stenting reduces the risk of abrupt closure, it cuts target lesion revascularisation and reduces restenosis in elective patients. So why not use stents in acute myocardial infarction patients, Cindy Grines, a one-time fan of thrombolysis who is now a confirmed fan of primary angioplasty asked. Because of the thrombosis risk, answered her opponents. Not a problem, said Dr Grines, when she presented data from a number of pilot studies at the ACC meeting in Anaheim, California, last month.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.